These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3930246)

  • 1. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function.
    De Caterina R; Giannessi D; Bernini W; Gazzetti P; Michelassi C; L'Abbate A; Donato L; Patrignani P; Filabozzi P; Patrono C
    Eur Heart J; 1985 May; 6(5):409-17. PubMed ID: 3930246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.
    Jakubowski JA; Stampfer MJ; Vaillancourt R; Faigel D; Deykin D
    J Lab Clin Med; 1986 Dec; 108(6):616-21. PubMed ID: 3097223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo.
    Kyrle PA; Eichler HG; Jäger U; Lechner K
    Circulation; 1987 May; 75(5):1025-9. PubMed ID: 3552295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity.
    Santos MT; Madrid I; Moscardo A; Latorre AM; Bonastre J; Ruano M; Valles J
    Platelets; 2014; 25(4):268-73. PubMed ID: 23909754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
    Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG
    Int J Cardiol; 2011 Jul; 150(1):39-44. PubMed ID: 20207433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease.
    Zoja C; Benigni A; Livio M; Bergamelli A; Orisio S; Abbate M; Bertani T; Remuzzi G
    Am J Pathol; 1989 May; 134(5):1027-38. PubMed ID: 2497648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.
    Moscardó A; Santos MT; Fuset MP; Ruano M; Vallés J
    Thromb Haemost; 2011 Apr; 105(4):663-9. PubMed ID: 21301784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin.
    Preston FE; Whipps S; Jackson CA; French AJ; Wyld PJ; Stoddard CJ
    N Engl J Med; 1981 Jan; 304(2):76-9. PubMed ID: 7003384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of platelet cyclooxygenase with controlled release, low-dose aspirin.
    Vial JH; McLeod LJ; Roberts MS; Seville PR
    Aust N Z J Med; 1990 Oct; 20(5):652-6. PubMed ID: 2126726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
    Clarke RJ; Mayo G; Price P; FitzGerald GA
    N Engl J Med; 1991 Oct; 325(16):1137-41. PubMed ID: 1891022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis.
    Keimowitz RM; Pulvermacher G; Mayo G; Fitzgerald DJ
    Circulation; 1993 Aug; 88(2):556-61. PubMed ID: 8339418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.
    Cipollone F; Patrignani P; Greco A; Panara MR; Padovano R; Cuccurullo F; Patrono C; Rebuzzi AG; Liuzzo G; Quaranta G; Maseri A
    Circulation; 1997 Aug; 96(4):1109-16. PubMed ID: 9286937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction.
    De Caterina R; Giannessi D; Boem A; Bernini W; Battaglia D; Michelassi C; Dell'Amico F; L'Abbate A; Patrignani P; Patrono C
    Thromb Haemost; 1985 Aug; 54(2):528-32. PubMed ID: 4082090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension.
    Benigni A; Gregorini G; Frusca T; Chiabrando C; Ballerini S; Valcamonico A; Orisio S; Piccinelli A; Pinciroli V; Fanelli R
    N Engl J Med; 1989 Aug; 321(6):357-62. PubMed ID: 2664523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
    Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
    Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose aspirin in pregnancy.
    Sibai BM; Mirro R; Chesney CM; Leffler C
    Obstet Gynecol; 1989 Oct; 74(4):551-7. PubMed ID: 2797631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.